以嶺藥業(002603.SZ):格列吡嗪片通過一致性評價
格隆匯12月14日丨以嶺藥業(002603.SZ)公佈,近日,公司收到國家藥品監督管理局核准簽發的格列吡嗪片的《藥品補充申請批准通知書》,該藥品通過了仿製藥質量和療效一致性評價。
格列吡嗪片是第二代磺酰脲類抗糖尿病藥。對大多數Ⅱ型糖尿病患者有效,可使空腹及餐後血糖降低,糖化血紅蛋白(HbA1c)下降1%-2%。其説明書適應症為:格列吡嗪用於輔助飲食和運動,改善成人2型糖尿病患者的血糖控制。
格列吡嗪片是國家醫保目錄(2021年版)甲類品種,是國家基本藥物目錄(2018年版)收載品種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.